methoxyamine
Small moleculeexperimental
Methoxyamine is the organic compound with the formula CH3ONH2. Also called O-methylhydroxylamine, it is a colourless volatile liquid that is soluble in polar organic solvent and in water. It is a derivative of hydroxylamine with the hydroxyl hydrogen replaced by a methyl group. Alternatively, it can be viewed as a derivative of methanol with the hydroxyl hydrogen replaced by an amino group. It is an isomer of N-methylhydroxylamine and aminomethanol. — Wikipedia
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00892385)
Timeline
Indications
Studied for
- Adenocarcinoma of Lung · Phase 2
- Burkitt Lymphoma · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Glioblastoma · Phase 2
- Hamartoma · Phase 1/Phase 2
- Hodgkin Disease · Phase 1
- Intraocular Lymphoma · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia-Lymphoma, Adult T-Cell · Phase 1
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large-Cell, Anaplastic · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, T-Cell · Phase 1
- Lymphoma, T-Cell, Peripheral · Phase 1
- Lymphomatoid Granulomatosis · Phase 1
- Mesothelioma · Phase 1/Phase 2
- Multiple Myeloma · Phase 1
- Neoplasms · Phase 1/Phase 2
- Pregnancy · Phase 3
- Sezary Syndrome · Phase 1
- Testicular Neoplasms · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Chemistry & pharmacology
Loading structure…
SMILES
CON- Mol. weight
- 47.06 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMethoxyamine ↗
- ChEMBLCHEMBL1213633 ↗
Also known as
- methoxyamine
- methoxyamine
- methoxyamine
- methoxyamine hydrochloride
- methoxylamine
- o-methylhydroxylamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06121063 | Phase 3 | Dec 31, 2023 | Conceptra Biosciences |
| NCT05198830 | Phase 2 | May 20, 2022 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT02395692 | Phase 2 | Dec 18, 2015 | National Cancer Institute (NCI) |
| NCT02535325 | Phase 1 | Sep 30, 2015 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT02535312 | Phase 1/Phase 2 (Phase 2) | Aug 11, 2015 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT01658319 | Phase 1 | May 1, 2011 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT00892385 | Phase 1 | Aug 1, 2007 | Case Western Reserve University, National Cancer Institute (NCI) |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 6 | 4 | 2 | 2007 |
| Case Western Reserve University | Academic/Hospital | 4 | 2 | 2 | 2007 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Conceptra Biosciences | For profit | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1